Institution
University of Milan
Education•Milan, Italy•
About: University of Milan is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 58413 authors who have published 139784 publications receiving 4636354 citations. The organization is also known as: Università degli Studi di Milano & Statale.
Topics: Population, Medicine, Cancer, Blood pressure, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Findings show that HIV integration sites can play a critical role in expansion and persistence of HIV-infected cells, and may determine the size of the latent reservoir.
Abstract: The persistence of HIV-infected cells in individuals on suppressive combination antiretroviral therapy (cART) presents a major barrier for curing HIV infections. HIV integrates its DNA into many sites in the host genome; we identified 2410 integration sites in peripheral blood lymphocytes of five infected individuals on cART. About 40% of the integrations were in clonally expanded cells. Approximately 50% of the infected cells in one patient were from a single clone, and some clones persisted for many years. There were multiple independent integrations in several genes, including MKL2 and BACH2; many of these integrations were in clonally expanded cells. Our findings show that HIV integration sites can play a critical role in expansion and persistence of HIV-infected cells.
690 citations
••
TL;DR: A consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection is document.
Abstract: Following the identification of the C-C chemokines RANTES, MIP-1alpha and MIP-1beta as major human immunodeficiency virus (HIV)-suppressive factors produced by CD8+ T cells, several chemokine receptors were found to serve as membrane co-receptors for primate immunodeficiency lentiretroviruses. The two most widely used co-receptors thus far recognized, CCR5 and CXCR4, are expressed by both activated T lymphocytes and mononuclear phagocytes. CCR5, a specific RANTES, MIP-1alpha and MIP-1 receptor, is used preferentially by non-MT2-tropic HIV-1 and HIV-2 strains and by simian immunodeficiency virus (SIV), whereas CXCR4, a receptor for the C-X-C chemokine SDF-1, is used by MT2-tropic HIV-1 and HIV-2, but not by SIV. Other receptors with a more restricted cellular distribution, such as CCR2b, CCR3 and STRL33, can also function as co-receptors for selected viral isolates. The third variable region (V3) of the gp120 envelope glycoprotein of HIV-1 has been fingered as a critical determinant of the co-receptor choice. Here, we document a consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection. Viral isolates obtained during the asymptomatic stages generally used only CCR5 as a co-receptor and were inhibited by RANTES, MIP-1alpha and MIP-1beta, but not by SDF-1. By contrast, the majority of the isolates derived after the progression of the disease were resistant to C-C chemokines, having acquired the ability to use CXCR4 and, in some cases, CCR3, while gradually losing CCR5 usage. Surprisingly, most of these isolates were also insensitive to SDF-1, even when used in combination with RANTES. An early acquisition of CXCR4 usage predicted a poor prognosis. In children who progressed to AIDS without a shift to CXCR4 usage, all the sequential isolates were CCR5-dependent but showed a reduced sensitivity to C-C chemokines. Discrete changes in the V3 domain of gp120 were associated with the loss of sensitivity to C-C chemokines and the shift in co-receptor usage. These results suggest an adaptive evolution of HIV-1 in vivo, leading to escape from the control of the antiviral C-C chemokines.
688 citations
••
TL;DR: The objective of this guideline is to provide healthcare professionals with clear, up-to-date, and practical guidance on the management of TTP and relatedThrombotic microangiopathies, defined by thrombocytopenia, microangypathic haemolytic anaemia (MAHA) and small vessel thromBosis.
Abstract: related to the subsections of this guideline. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the BCSH. The guideline was then reviewed by a sounding board of British haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The ‘GRADE’ system was used to quote levels and grades of evidence, details of which can be found at http://www.bcshguidelines.com. The objective of this guideline is to provide healthcare professionals with clear, up-to-date, and practical guidance on the management of TTP and related thrombotic microangiopathies, defined by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA) and small vessel thrombosis.
688 citations
••
University of Glasgow1, University of Belgrade2, Karolinska University Hospital3, Mayo Clinic4, University of Verona5, Heidelberg University6, Freeman Hospital7, Trinity College, Dublin8, University of Barcelona9, Technische Universität München10, University of Amsterdam11, Harvard University12, University of Milan13, University of Liverpool14, Kyoto University15, Hospital of the University of Pennsylvania16, Thomas Jefferson University17
TL;DR: Current evidence justifies portomesenteric venous resection in patients with BRPC, and a new classification of extrahepatic mesentericoportal ven Mous resections is proposed by the ISGPS.
688 citations
••
06 Jul 1999TL;DR: NUSMV, a new symbolic model checker developed as a joint project between Carnegie Mellon University and Istituto per la Ricerca Scientifica e Tecnolgica (IRST), is described, a well structured, open, flexible and documented platform for model checking.
Abstract: This paper describes NUSMV, a new symbolic model checker developed as a joint project between Carnegie Mellon University (CMU) and Istituto per la Ricerca Scientifica e Tecnolgica (IRST) NUSMV is designed to be a well structured, open, flexible and documented platform for model checking In order to make NUSMV applicable in technology transfer projects, it was designed to be very robust, close to the standards required by industry, and to allow for expressive specification languages NUSMV is the result of the reengineering, reimplementation and extension of SMV [6], version 244 (SMV from now on) With respect to SMV, NUSMV has been extended and upgraded along three dimensions First, from the point of view of the system functionalities, NUSMV features a textual interaction shell and a graphical interface, extended model partitioning techniques, and allows for LTL model checking Second, the system architecture of NUSMV has been designed to be highly modular and open The interdependencies between different modules have been separated, and an external, state of the art BDD package [8] has been integrated in the system kernel Third, the quality of the implementation has been strongly enhanced This makes of NUSMV a robust, maintainable and well documented system, with a relatively easy to modify source code NUSMV is available at http://nusmvirstitcit/
687 citations
Authors
Showing all 58902 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Cui | 220 | 1015 | 199725 |
Peter J. Barnes | 194 | 1530 | 166618 |
Thomas C. Südhof | 191 | 653 | 118007 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Alberto Mantovani | 183 | 1397 | 163826 |
John J.V. McMurray | 178 | 1389 | 184502 |
Giuseppe Remuzzi | 172 | 1226 | 160440 |
Russel J. Reiter | 169 | 1646 | 121010 |
Jean Louis Vincent | 161 | 1667 | 163721 |
Tobin J. Marks | 159 | 1621 | 111604 |
Tomas Hökfelt | 158 | 1033 | 95979 |
José Baselga | 156 | 707 | 122498 |
Naveed Sattar | 155 | 1326 | 116368 |
Silvia Franceschi | 155 | 1340 | 112504 |
Frederik Barkhof | 154 | 1449 | 104982 |